Replies to post #29 on BiondVax Pharmaceuticals Ltd (BVXV)

[midastouch017]

Tamar Ben-Yedidia, CSO of BiondVax commented,

"The trial will provide insight into the ability of BiondVax's universal vaccine to stimulate broad immunity to influenza viruses including the highly pathogenic H5N1 bird flu virus. It is clear that a universal vaccine for influenza, that will also cover this aggressive and particularly dangerous strain is greatly needed."